Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312809 | 0.83 | NPC1 (0.46) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12312808 | 0.83 | NPC1 (0.46) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL12461086 | 0.83 | NPC1 (0.46) | NPC1MEN1KMT2AMAPTRAB9A | |
| Bromide SCHEMBL5618997 | 0.79 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL14231482 | 0.79 | NPC1 (0.43) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL5636818 | 0.76 | NPC1 (0.41) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL22626440 | 0.76 | NPC1 (0.41) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL19367701 | 0.73 | NPC1 (0.63) | NPC1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL23734264 | 0.72 | — | — | |
| SCHEMBL6231051 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | NPC1 1453/4885MEN1 165/4885KMT2A 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.